Chris has over 20 years of applied health economics experience in consulting and academia. His interests centre on the use of health economics to maximise the societal value of scarce healthcare resources, including the use of cost-effectiveness and cost-utility frameworks to evaluate value-for-money and stated preference methods to elicit patient and public values. He has more than 50 peer-reviewed publications on topics including cost-effectiveness evaluations, preference studies, methodological contributions and invited editorials.
He sits on the editorial board of Pharmacoeconomics and is an Honorary Research Fellow with the Health Economics Group at the University of East Anglia, UK. He has been a Lead Economic Reviewer for the pan-Canadian Oncology Drug Review (pCODR) and the Canadian Common Drug Review (CDR). Chris has a PhD in Health Economics & Decision Science from The University of Sheffield and a master’s degree in Development Economics from Dalhousie University, Canada.